AR
CTKB icon

Advisory Research’s Cytek Biosciences CTKB Stock Holding History

Advisory Research’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-41,750
Closed -$614K – 375
2022
Q3 		$614K Buy
+41,750
New +$542K 0.06% 214

Other funds holding CTKB

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BWLSA
Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Advisory Research's CTKB Position: Q4 2022 in Review

Advisory Research sold out of Cytek Biosciences (CTKB) in Q4 2022, closing a stake of 41,750 shares — an estimated $614K sold.

Advisory Research first reported a position in CTKB in Q3 2022 and held it in 1 quarter. The position peaked at $614K in Q3 2022. 103 funds tracked by Wall St. Rank hold CTKB as of Q4 2022.

  • Advisory Research reported no remaining Cytek Biosciences position as of Q4 2022 after selling out during the quarter.
  • Advisory Research sold 41,750 Cytek Biosciences shares in Q4 2022, an estimated $614K.
  • Advisory Research first reported a position in Cytek Biosciences in Q3 2022 and held it in 1 quarter.
  • Advisory Research's Cytek Biosciences position peaked at $614K in Q3 2022.
  • 103 funds tracked by Wall St. Rank held Cytek Biosciences as of Q4 2022.

Based on Advisory Research's 13F filing for Q4 2022, filed 13 Feb 2023.